APOLLO HOSPITALS ENTER. L vs JAGSONPAL PHARMACEUTICALS
A side-by-side comparison of APOLLO HOSPITALS ENTER. L (APOLLOHOSP) and JAGSONPAL PHARMACEUTICALS (JAGSNPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
APOLLO HOSPITALS ENTER. L vs JAGSONPAL PHARMACEUTICALS are evenly matched on the numbers (7–7). The breakdown below shows where each one wins.
- Valuation13
- Profitability13
- Growth20
- Size & financial health31
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
JAGSNPHARM takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
JAGSNPHARM takes 3/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
APOLLOHOSP takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
APOLLOHOSP takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has delivered good profit growth of 76.2% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 17.7%"]
- − ["Stock is trading at 13.4 times its book value", "Company might be capitalizing the interest cost"]
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 50.3%", "Promoter holding has increased by 1.17% over last quarter.", "Company's working capital requirements have reduced from 24.0 days to 11.0 days"]
- − ["The company has delivered a poor sales growth of 8.85% over past five years."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.